Search

The concept of informed consent seems to be important in scientific research involving medical interventions and in clinical practice. This makes the study of this legal institution timely and relevant. Purpose: based on the results of the analysis of the formation and development of the institution of informed consent, to identify trends in its further development. Methods: systemic and structural-functional analysis, as well as special legal methods: comparative legal, formal legal, legal modeling, interpretation. Results: the article gives scientifically based proposals for improving the legal institution of informed consent. The article substantiates the conclusion that the content of consent should be absolutely transparent and understandable to all subjects involved, so that it really acts as an effective means of legal regulation of social relations related to medical intervention or research.

Introduction. In modern conditions of rapid development of genomics, the formation of a database of genetic testing of the Russian population, the legislative framework that effectively protects human rights and legitimate interests is only being formed in Russia. Theoretical analysis. Genetic information is of interest not only for a person who has undergone genetic testing, but also for his / her family members, the state in the organization of personalized medicine, employers, insurers, bankers. This situation is associated with violations of the constitutional rights of citizens to personal dignity, privacy, personal and family secrets, and non-discrimination. Empirical analysis. The problems of legal support of the constitutional rights of citizens in connection with the progress of genomics in various fields are revealed: in healthcare, marital, labor, insurance, banking relations, which requires prompt legislative regulation. Results. The vectors of the development of human rights protection in connection with the development of genomics are substantiated, taking into account the discussion of the most appropriate solutions in the legislation of foreign countries, allowing for a fair balance of interests of the owner of personal genetic information and third parties, with maximum minimization of potential risks of violation of constitutional rights.

The recent development of paleogenetics has had a large impact on much of archaeology. Particularly surprising has been the discovery of a connection between the Iberian Peninsula and the Eurasian steppes, an unexpected link between the first stages of metallurgy at opposite ends of Europe. Recent studies of human remains from Copper and Bronze Age Spain and Portugal have shown a significant presence of genomes of types geneticists attribute to the Yamnaya culture and historical community. Geneticists had already identified this genome in central European archaeological contexts. Interpretation of these results has led to controversy concerning their historical significance and their importance for explaining important cultural changes, such as the origin of the Bronze Age in Iberia. As a result, many Spanish and Portuguese prehistorians have “discovered” the cultures of the steppes. Their inclusion has broadened and enriched debates concerning Iberian prehistory. This article reviews recent literature so as to assess the state of play on the contribution of paleogenetics to Iberian prehistory and to reflect on the impact of the Yamnaya culture’s unexpected burst onto its scene.

Advances in genomic research, biobanking and DNA identification technologies are expanding the use of biological and genetic evidence in litigation. The discovery of DNA and one of its functions to transmit hereditary information made it possible to look differently at the theory of a genetic predisposition to deviant behavior. The relevance of the study is due to the fact that the availability and increase of genetic research allows, along with the traditional use of genetic expertise in litigation (search and identification of a criminal, establishment of paternity), to expand the possibility of using the achievements of genetics by the parties to prove other circumstances in court. In this article, the authors analyze the US jurisprudence regarding the possibility of a party using the protection of genetic evidence in order to present a position in justification of the mitigation of punishment for an accused due to her genetic predisposition to criminal behavior. The authors also paid attention to the consideration of the issue of using the results of genetic testing in civil proceedings in order to prove the fact of the influence of the inherited gene on deviant behavior. In carrying out this study, the authors used a significant number of Russian and foreign sources of scientific literature. General and specific scientific methods of cognition, including the formal legal and comparative legal method, were used as research methods

This article is devoted to the analysis of the genomic research legal regulation in the Russian Federation and the USA. In the United States, in addition to the legislation great importance is attached to medical and scientific institutions self-regulation, and such information is usually open. It is concluded that in Russia, despite the presence of both state and non-state scientific institutions engaged in genomic research, the mechanism of self-regulation as a whole is fragmented. It is also noted that Russia and the United States have specific legal regulation of these relations, which is reflected in the text of the article. For example, in the United States, unlike Russia, most organizations conducting genomic research, including genomic testing, are non-governmental. Currently, the general trend in the legal regulation of genomic research in Russia and the USA is the active development of normative legal regulation. Moreover, a significant difference in the approaches of these countries is the active role of the US states in the development of regional legal regulation on these issues. Despite the fact that Russia is a federal state, the subjects of the Russian Federation are significantly limited in the genomic research legal regulation possibilities. This is largely due to both legal and political reasons that were given in this article. In the United States, a number of statutes have been adopted at the state level that regulate genomic research in such aspects as health insurance, confidential of personal information, the prohibition of discrimination, screening of newborns, and certain types of clinical and scientific research. It should be noted that the genomic research regulation in the United States is not integrated into a single national consolidated act, which is a feature of this legal system. A comparative legal study of the fundamentals of legal regulation and self-regulation of genomic research in Russia and the USA made it possible to understand the specifics of regulation of these issues in different legal systems. The positive regulatory experience in conducting genomic research in the United States can be used to improve the regulatory framework of the Russian Federation in this area.

Genomic research is one of the priorities of the country’s scientific and technological development, which have been supported by the instruction of the President to the Government on the development of a program for the development of advanced genomic research and genetic technologies in the Russian Federation, by the national project “Science”, and by the project of tintegrated scientific -technological program “The Postgenomic technologies: editing to synthetic biology”. The target indicator of NP “Science” is to ensure the presence of the Russian Federation among the five leading countries of the world that carry out research and development in areas determined by the priorities of scientific and technological development, and one of the indicators of the implementation of this indicator is “the place of the Russian Federation by share in the total number of applications for a patent for an invention filed in the world”. Comparison of patent activity of residents of theRussian Federationand the leading countries of the world engaged in research and development using the capabilities of highperformance genome sequencing was performed. A map of the competitive landscape in the technological field under consideration has been built, showing that foreign companies such as DowDuPont, Roche Holding and Illumina have already created impressive by volume patent portfolios. It was noted that in order for the developments, that will be created in the world-class genomic technology centers within the NP Science, to be globally competitive, it is already necessary to create conditions for the active participation of the business sector in government projects and programs.

The need to maintain a high quality of life against a backdrop of its inevitably increasing duration is one of the main problems of modern health care. The concept of "right drug to the right patient at the right time", which at first was bearing the name "personalized", is currently unanimously approved by international scientific community as "precision medicine". Precision medicine takes all the individual characteristics into account: genes diversity, environment, lifestyles, and even bacterial microflora and also involves the use of the latest technological developments, which serves to ensure that each patient gets assistance fitting his state best. In the United States, Canada and France national precision medicine programs have already been submitted and implemented. The aim of this review is to describe the dynamic integration of precision medicine methods into routine medical practice and life of modern society. The new paradigm prospects description are complemented by figures, proving the already achieved success in the application of precise methods for example, the targeted therapy of cancer. All in all, the presence of real-life examples, proving the regularity of transition to a new paradigm, and a wide range of technical and diagnostic capabilities available and constantly evolving make the all-round transition to precision medicine almost inevitable.